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ABSTRACT
Background: Cytomegalovirus (CMV) infection in susceptible patients is associated 
with serious morbidity and a high mortality. Transmission of cytomegalovirus infection 
through blood transfusion is markedly reduced by transfusion of CMV seronegative 
blood products, or by transfusion of leucodepleted blood products.
Objective: To determine the prevalence CMV IgG and IgM antibodies among blood 
donors at the National Blood Transfusion Services (NBTS), Nairobi.
Design: Cross-sectional descriptive study.
Setting: Four hundred participants were recruited from blood donors at the NBTS and 
testing was done at the Kenyatta National Hospital (KNH) immunology laboratories 
and the NBTC.
Main outcome measures: Social demographic data and the CMV serologic status for 
the participants was determined and documented as being positive or negative for 
immunoglobulin G (IgG) and immunoglobulin M (IgM). The age, gender, marital 
status, education level and geographical area of residence of the participants were 
documented. Corresponding results of HIV, hepatitis B antigen, hepatitis C antibody 
from the patients were obtained from the NBTS. 
Results: Majority of the blood donors recruited were male at 57.9%. Most blood donors 
were aged 16-20 years (42.5%) and only 17.2% were above 30 years of age. Unmarried 
blood donors, those with secondary school education and an income between Kshs 
5,000 (US$ 67)and KShs 50,000 (US$ 667) monthly were the majority at 78.5%, 54.8% 
and 66.1% respectively. Sexually active blood donors constituted 60.5% of the donors 
recruited.  Positivity for transfusion transmissible infections (TTI) tested was 1.3%, 
0.3%, 2.3% and 1.0% for human immunodeficiency virus (HIV), syphilis, hepatitis 
B and hepatitis C respectively. Anti- CMV IgG and IgM positivity was 97.0%,( 95% 
CI 96.45-97.53%), and 3.6% (95% CI 1.7-5.2%), respectively. There was no statistical 
difference between different ages, marital status, salary, individual’s sexuality in the 
prevalence of CMV antibodies. However females had a higher prevalence of CMV 
antibodies.
Conclusion: There is a very high prevalence of cytomegalovirus antibodies among 
blood donors at the NBTS, with virtually all blood donors having been exposed to the 
virus. Since the CMV remains latent within leucocytes after infection inspite of the 
prescence of antibodies in seropositive individuals, leucoreduction of blood products 
is recommended before transfusion to seronegative susceptible patients. In Kenya, 
susceptible groups of patients include very low birthweight babies, patients with 
acquired immune deficiency syndrome (AIDS) due to human immunodeficiency virus 
infections (HIV) patients, patients on myelosuppressive cancer therapy and recipients 
of kidney transplants. Further studies are recomended to determine the prevalence of 
CMV antibodies in these patients in order to establish the magnitude of the demand 
for CMV safe blood. 
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INTRODUCTION
Cytomegalvirus (CMV) is a double stranded DNA 
virus that is found throughout the world in all 
geographical locations and socio-economic groups. 
It infects between 50% and 85% of all adults  in the 
developed world by the age of 40 years (1,2). The rate 
of seropositivity increases with age and decreasing 
socio-economic status (2-4). Immune response does 
not eliminate the virus but the virus remains latent 
in leucocytes and can be transmitted through blood 
or blood products to a recipient of these products. 
CMV safe blood or blood products are obtained  from 
CMV seronegative individuals, or leucoreduced blood 
products before transfusion (5-7).
 In healthy subjects, infection with the CMV virus 
is often subclinical but may occasionally manifest 
with a mild self limited disease with fever, malaise, 
hepatosplenomegaly and rash (1). In susceptible 
patients who include low birth weight babies, HIV/
AIDS patients, patients on myelosuppressive cancer 
therapy and recipients of organ and haemopoetic cell 
transplants, CMV infections is associated with serious 
morbidity and a high mortality rate. Infection may 
result in hepatitis, retinitis, and multisystem failure 
(8-11). Susceptible patients should therefore receive 
CMV safe blood products, which should either be 
CMV seronegative or leucoreduced (12-14).
 Currently in most resource constrained 
developing countries, including Kenya, CMV safe 
blood is not yet available in the blood transfusion 
service despite the fact that there is a significant 
proportion of patients who require the product. The 
prevalence of CMV antibodies in Kenyan blood donor 
population is unknown. Prevalence of CMV virus 
seropositivity among donors is important because 
it indicates the pool of the potential source of CMV 
seronegative donors. This study aims at determining 
the prevalence of CMV IgG and IgM antibodies in 
blood donors at the NBTS, Nairobi.
MATERIALS AND METHODS
Study population and setting: This cross-sectional 
descriptive study was carried out at the NBTS and 
the immunology department, KNH. The laboratory 
testing for anti-CMV antibodies was done at the KNH 
immunology laboratories while that for the other 
transfusion transmittable infections, (TTI- HIV, VDRL 
hepatitis B and hepatitis C), were carried out routinely 
at the NBTS laboratory. The study was carried out 
on 400 blood donors, who met the criteria for blood 
donation set by the NBTS and were recruited by 
simple random sampling at the various NBTC blood 
collection sessions. These blood donors included 
students from different institutions such as secondary 
schools and colleges within Nairobi province. They 
also included the general public recruited in towns, 
hotels and churches in the areas covered by the NBTS. 
Social demographic data including age, sex, marital 
status, level of income and sexuality were obtained 
from consenting individuals and recorded.
Specimen collection, transport, storage and testing: 
Approximately 3mls of blood was drawn from each 
study participant into labelled vacutainer tubes and 
transported in cool boxes to the KNH immunology 
laboratories where they were tested for CMV-
specific IgG and IgM antibodies by an Elisa method. 
The results were reported as positive or negative. 
Results of HIV screening, hepatitis B surface antigen, 
hepatitis C antibody, and syphilis testing were also 
recorded.
Data management: The data was entered into a pre-
designed proforma, coded and entered into the 
statistical package for social sciences (SPSS), version 
15. Descriptive statistics were applied to continuous 
and categorical data and proportions obtained. For 
precision 95% confidence intervals were applied. A 
p –value of less than 0.05 was considered significant. 
Data was presented in tables and figures.
RESULTS
Figure 1 summarises the age and sex distribution of 
the participants. There was a higher proportion of 
male donors than females. Most of the donors were 
young with a mean age of 24.2 years and median of 
22 years. The age range was 16 to 54 years.  
Figure 1
Age and gender distribution of the study participants
Majority of the participants, 382 (97% with 95% CI 
96.45-97.53%) had CMV IgG antibodies. Only 14 
(3.6% with 95% CI 1.7-5.2%) were CMV IgM antibody 
positive. Table 1 summarises CMV positivity among 
different age groups while Table 2 shows frequency 
of seropositivity among two genders.
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Five (1.3%) participants were HIV positive whereas 
390(98.7%) were HIV negative.  One (0.3%) donor 
tested positive for syphilis and 394(99.7%) tested 
negative. Nine (2.3%) participants were positive for 
hepatitis B and 386(97.1%) were negative while four 
(1.0%) tested positive for hepatitis C and 391(99%) 
tested negative. Three hundred and eighty three (97%-
95%CI 96.45-97.53 ) participants were positive for IgG 
anti-CMV antibodies and 12(3%) were negative while 
14(3.5%- CI 1.7-5.2%) tested positive for IgM anti-CMV 
antibodies and 381(96.5%) tested negative.
DISCUSSION
The results of this study are very similar to those of 
an Indian study by Kothari  et al (17). They found 
very high prevalence of CMV IgG antibodies of 95% 
with very low IgM antibodies prevalence (17). This is 
in contrast to the lower levels in Western developed 
countries (1,2). This could be associated with broad 
socioeconomic factors (3).  In this study however there 
were no significant differences in the prevalence with 
respect to education level, socioeconomic groups, 
marital status, sexuality, as demonstrated by other 
studies. The reason for this is not clear.
 No statistically significant differences were found 
among different age groups. This study however did 
not include participants below 16 years of age because 
they are below the age limit for blood donation. 
It is recommended that studies below this age be 
conducted to determine the pattern of seroconversion 
in children.
 A higher prevalence of CMV antibodies is noted 
in females which is  consistent with other studies. The 
reason for the higher prevalence has been thought to 
be related to sexual transmission. 
 It has been argued that CMV IgM positive blood 
is more infective than IgG positive blood (3). The 
prevalence of CMV IgM only positivity is so low 
that in our setting it would be unaffordable to use 
IGM seronegative donors. Virtually all the donors 
are IgG positive and therefore potentially harbour 
CMV virus in a latent form in their leucocytes. It is 
therefore proposed that CMV safe blood should be 
obtained by leucoreduction, rather than by serotesting 
for CMV antibodies, for Kenyan susceptible patients. 
In Kenya the susceptible groups include low birth 
weight babies, HIV/AIDS immune compromised 
patients, patients on myeosuppressive cancer therapy 
and patients undergoing organ transplants. 
 
Table 1
Anti-CMV antibodies and age of study participants
Age group            IgG             IgM
              Positive             Negative          Positive          Negative
  No. (%) No. (%) No. (%)  No. (%) 
16 – 20 163 97.0 5 3.0 5 3.0 163 97.0
21 – 25 92 95.8 4 4.2 2 2.1 94 97.9
26 – 30 56 98.2 1 1.8 2 3.5 55 96.5
>30  66 97.1 2 2.9 5 7.4 63 92.6
Total  377 96.9 12 3.1 14 3.6 375 96.4
Table 2
Anti-CMV antibodies and gender
Gender              Male              Female       Total
  No. (%) No. (%) No. (%)
IgG Positive 217 95.2 166 99.4 382 97
 Negative 11 4.8 1 0.6 12 3
IgM Positive 8 3.5 6 3.6 14 3.6
 Negative 220 96.5 160 96.4 380 96.4
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